Currently, several early-phase trials of agents targeting ATR in combination with a topoisomerase I inhibitor (NCT04514497, NCT02487095, and NCT03896503) are ongoing in cancers, including GEP-NECs (Table 7). This evidence concerns the gene ATR and cancer.